C4 Therapeutics CCCC
NASDAQ CCCC
$2.89 -0.11 (-3.67%)
At close: Nov 11, 2026 · 4:00 PM EST

C4 Therapeutics (CCCC) Gains from Sales and Divestitures (2019)

Updated

C4 Therapeutics' Gains from Sales and Divestitures was -$7,000 in Q4 2019.

Analysis

C4 Therapeutics (CCCC) Gains from Sales and Divestitures (2019) Analysis & Trends

For FY2019, Gains from Sales and Divestitures at C4 Therapeutics came in at -$16,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 C4 Therapeutics 393.93 Mn -549.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 -7,000.00
API Access

C4 Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CCCC&period=max&api_key=YOUR_API_KEY